Gene
HDAC2
HDAC2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (1), Trial mentions (9), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention HDAC2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
HDAC2 has 9 trial mentions across 8 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 8 of 11,460 | 0.07% |
| 2022 | 0 of 8,285 | 0.00% | 12 of 13,598 | 0.09% |
| 2021 | 0 of 8,692 | 0.00% | 17 of 15,045 | 0.11% |
| 2020 | 2 of 7,640 | 0.03% | 24 of 14,459 | 0.17% |
| 2019 | 0 of 7,300 | 0.00% | 14 of 12,159 | 0.12% |
| 2018 | 1 of 6,927 | 0.01% | 9 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| OmixScience Co., Ltd | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 06, 2026 |
| OmixScience Research Institute | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 06, 2026 |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| HDAC2 biallelic inactivation | OLAPARIB | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (9)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04187833 | Trial eligibility (AACT) |
| NCT03432897 | Trial eligibility (AACT) |
| NCT06527690 | Trial eligibility (AACT) |
| NCT04288687 | Trial eligibility (AACT) |
| NCT02340520 | Trial outcomes (AACT) |
Showing 5 of 9 trial mentions.
Target-disease associations (332)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Literature (Europe PMC) |
| ATTRV122I amyloidosis | cardiovascular disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Anxiety | phenotype | Literature (Europe PMC) |
| Arrhythmogenic right ventricular dysplasia | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 332 associations.
Vendor sourcing (25)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma (mixed histology will be acceptable, but pure small cell histology is to... | View trial NCT04288687 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | HDAC2 | View trial NCT04288687 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1347A>C (p.E449D) alteration is located in exon 12 (coding exon 12) of the HDAC2 gene. This alteration results from a A to C substitution at nucleotide... | View ClinVar record SCV003711948.3 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Biopsy confirmed adenocarcinoma of the prostate. * High risk for recurrence after prostatectomy including any of the following * Lymph node involveme... | View trial NCT03432897 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | HDAC2 | View trial NCT03432897 |
Showing 5 of 25 sourcing records.
Trial-cited literature (187)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. | JCO precision oncology | 2024 | 3 |
| Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | 305 |
| Pathogenesis of allergic diseases and implications for therapeutic interventions. | Signal transduction and targeted therapy | 2023 | 286 |
| Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy. | International journal of molecular sciences | 2023 | 151 |
| Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. | Haematologica | 2023 | 59 |
Showing 5 of 187 papers.
Literature-extracted relations (34)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| "Hydrocortisone" | Chemical | associate |
Rapid changes in histone deacetylases and inflammatory gene expression in expert meditators. | 2014 |
| Theophylline | Chemical | negative_correlate |
The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. | 2012 |
| Theophylline | Chemical | negative_correlate |
Theophylline. | 2010 |
| Theophylline | Chemical | positive_correlate |
Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. | 2010 |
| Theophylline | Chemical | positive_correlate |
How corticosteroids control inflammation: Quintiles Prize Lecture 2005. | 2006 |
Showing 5 of 34 relation assertions.
Organizations publishing (234)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| University of California System | Academic | 7 | 2014 to 2024 |
| Government of the United States of America | Government | 6 | 2014 to 2021 |
| Dana-Farber Cancer Institute | Other | 5 | 2019 to 2021 |
| Imperial College London | Academic | 5 | 2010 to 2023 |
| Harvard Medical School | Academic | 4 | 2016 to 2023 |
Showing 5 of 234 organizations.
Where HDAC2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
303 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.